Neuphoria Therapeutics Inc.
NEUP
$4.61
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,161.46% | -- | -- | 211,558.11% | 4,347.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,161.46% | -- | -- | 35,535.97% | 847.13% |
| Cost of Revenue | 28.99% | -17.80% | -3,637,900.00% | -271.69% | -148.06% |
| Gross Profit | 221.90% | 524.53% | 19,287,300.00% | 831.36% | 192.72% |
| SG&A Expenses | -4.92% | 2.92% | -8.09% | -11.51% | -28.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.71% | 16.77% | -7.41% | -10.98% | -27.90% |
| Operating Income | 87.45% | 81.67% | 95.34% | 97.41% | 31.27% |
| Income Before Tax | 27.18% | 10.60% | 94.62% | 130.74% | 59.69% |
| Income Tax Expenses | -201.81% | -100.87% | -436.54% | -167.46% | 0.72% |
| Earnings from Continuing Operations | 31.04% | 12.50% | 97.61% | 132.19% | 60.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.04% | 12.50% | 97.61% | 132.19% | 60.09% |
| EBIT | 87.45% | 81.67% | 95.34% | 97.41% | 31.27% |
| EBITDA | 91.53% | 85.22% | 99.03% | 101.10% | 32.29% |
| EPS Basic | 73.61% | 68.92% | 100.23% | 116.52% | -50.98% |
| Normalized Basic EPS | 79.98% | 72.82% | 97.34% | 80.54% | -103.42% |
| EPS Diluted | 61.52% | 64.29% | 95.35% | 109.64% | -61.50% |
| Normalized Diluted EPS | 79.98% | 72.82% | 97.34% | 80.54% | -103.42% |
| Average Basic Shares Outstanding | 123.34% | 88.88% | -99.57% | -99.83% | -99.90% |
| Average Diluted Shares Outstanding | 123.34% | 88.88% | -99.57% | -99.83% | -99.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |